Biochemical and pharmacological evidence for opioid receptor multiplicity in the central nervous system

G. W. Pasternak, A. R. Gintzler, R. A. Houghten, Geoffrey Ling, R. R. Goodman, K. Spiegel, S. Nishimura, N. Johnson, L. D. Recht

Research output: Contribution to journalArticle

Abstract

Evidence from a variety of experimental models has suggested the existence of mu1, mu2 and delta binding sites for morphine and the enkephalins in the central nervous system. Additional biochemical experiments now support this concept of a common high affinity site for opiates and opioid peptides. Mu sites have now been implicated in a number of pharmacological actions, including supraspinal analgesia, prolactin release, and catalepsy, but not in others (spinal analgesia, respiratory depression, and the guinea pig ileum). The hypothesis of mu1 sites was supported by the unique opioid meptazinol, which selectively bound to mu1 sites. As expected from its mu1 binding selectivity, its analgesic actions in the mouse, localized supraspinally, were antagonized by the selective mu1 antagonist naloxonazine and it had no respiratory depressant actions. Other binding studies suggested the presence of discrete SKF10, 047-selective (KD approximately 5 nM) binding sites in rat brain which differed from both kappa sites and the previously reported PCP-binding sigma sites. Additional binding and autoradiograpical studies have also implied the presence of β-endorphin, or epsilon, sites in the CNS.

Original languageEnglish (US)
Pages (from-to)167-173
Number of pages7
JournalLife Sciences
Volume33
Issue numberSUPPL. 1
DOIs
StatePublished - Jan 1 1983
Externally publishedYes

Fingerprint

Opioid Peptides
Neurology
Opioid Receptors
Meptazinol
Central Nervous System
Binding Sites
Pharmacology
Endorphins
Analgesia
Enkephalins
Prolactin
Morphine
Opioid Analgesics
Catalepsy
Analgesics
Rats
Brain
Ileum
Respiratory Insufficiency
Guinea Pigs

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pasternak, G. W., Gintzler, A. R., Houghten, R. A., Ling, G., Goodman, R. R., Spiegel, K., ... Recht, L. D. (1983). Biochemical and pharmacological evidence for opioid receptor multiplicity in the central nervous system. Life Sciences, 33(SUPPL. 1), 167-173. https://doi.org/10.1016/0024-3205(83)90470-8

Biochemical and pharmacological evidence for opioid receptor multiplicity in the central nervous system. / Pasternak, G. W.; Gintzler, A. R.; Houghten, R. A.; Ling, Geoffrey; Goodman, R. R.; Spiegel, K.; Nishimura, S.; Johnson, N.; Recht, L. D.

In: Life Sciences, Vol. 33, No. SUPPL. 1, 01.01.1983, p. 167-173.

Research output: Contribution to journalArticle

Pasternak, GW, Gintzler, AR, Houghten, RA, Ling, G, Goodman, RR, Spiegel, K, Nishimura, S, Johnson, N & Recht, LD 1983, 'Biochemical and pharmacological evidence for opioid receptor multiplicity in the central nervous system', Life Sciences, vol. 33, no. SUPPL. 1, pp. 167-173. https://doi.org/10.1016/0024-3205(83)90470-8
Pasternak GW, Gintzler AR, Houghten RA, Ling G, Goodman RR, Spiegel K et al. Biochemical and pharmacological evidence for opioid receptor multiplicity in the central nervous system. Life Sciences. 1983 Jan 1;33(SUPPL. 1):167-173. https://doi.org/10.1016/0024-3205(83)90470-8
Pasternak, G. W. ; Gintzler, A. R. ; Houghten, R. A. ; Ling, Geoffrey ; Goodman, R. R. ; Spiegel, K. ; Nishimura, S. ; Johnson, N. ; Recht, L. D. / Biochemical and pharmacological evidence for opioid receptor multiplicity in the central nervous system. In: Life Sciences. 1983 ; Vol. 33, No. SUPPL. 1. pp. 167-173.
@article{e39af1b3bbe94016a0dd69eff6081a6d,
title = "Biochemical and pharmacological evidence for opioid receptor multiplicity in the central nervous system",
abstract = "Evidence from a variety of experimental models has suggested the existence of mu1, mu2 and delta binding sites for morphine and the enkephalins in the central nervous system. Additional biochemical experiments now support this concept of a common high affinity site for opiates and opioid peptides. Mu sites have now been implicated in a number of pharmacological actions, including supraspinal analgesia, prolactin release, and catalepsy, but not in others (spinal analgesia, respiratory depression, and the guinea pig ileum). The hypothesis of mu1 sites was supported by the unique opioid meptazinol, which selectively bound to mu1 sites. As expected from its mu1 binding selectivity, its analgesic actions in the mouse, localized supraspinally, were antagonized by the selective mu1 antagonist naloxonazine and it had no respiratory depressant actions. Other binding studies suggested the presence of discrete SKF10, 047-selective (KD approximately 5 nM) binding sites in rat brain which differed from both kappa sites and the previously reported PCP-binding sigma sites. Additional binding and autoradiograpical studies have also implied the presence of β-endorphin, or epsilon, sites in the CNS.",
author = "Pasternak, {G. W.} and Gintzler, {A. R.} and Houghten, {R. A.} and Geoffrey Ling and Goodman, {R. R.} and K. Spiegel and S. Nishimura and N. Johnson and Recht, {L. D.}",
year = "1983",
month = "1",
day = "1",
doi = "10.1016/0024-3205(83)90470-8",
language = "English (US)",
volume = "33",
pages = "167--173",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Biochemical and pharmacological evidence for opioid receptor multiplicity in the central nervous system

AU - Pasternak, G. W.

AU - Gintzler, A. R.

AU - Houghten, R. A.

AU - Ling, Geoffrey

AU - Goodman, R. R.

AU - Spiegel, K.

AU - Nishimura, S.

AU - Johnson, N.

AU - Recht, L. D.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Evidence from a variety of experimental models has suggested the existence of mu1, mu2 and delta binding sites for morphine and the enkephalins in the central nervous system. Additional biochemical experiments now support this concept of a common high affinity site for opiates and opioid peptides. Mu sites have now been implicated in a number of pharmacological actions, including supraspinal analgesia, prolactin release, and catalepsy, but not in others (spinal analgesia, respiratory depression, and the guinea pig ileum). The hypothesis of mu1 sites was supported by the unique opioid meptazinol, which selectively bound to mu1 sites. As expected from its mu1 binding selectivity, its analgesic actions in the mouse, localized supraspinally, were antagonized by the selective mu1 antagonist naloxonazine and it had no respiratory depressant actions. Other binding studies suggested the presence of discrete SKF10, 047-selective (KD approximately 5 nM) binding sites in rat brain which differed from both kappa sites and the previously reported PCP-binding sigma sites. Additional binding and autoradiograpical studies have also implied the presence of β-endorphin, or epsilon, sites in the CNS.

AB - Evidence from a variety of experimental models has suggested the existence of mu1, mu2 and delta binding sites for morphine and the enkephalins in the central nervous system. Additional biochemical experiments now support this concept of a common high affinity site for opiates and opioid peptides. Mu sites have now been implicated in a number of pharmacological actions, including supraspinal analgesia, prolactin release, and catalepsy, but not in others (spinal analgesia, respiratory depression, and the guinea pig ileum). The hypothesis of mu1 sites was supported by the unique opioid meptazinol, which selectively bound to mu1 sites. As expected from its mu1 binding selectivity, its analgesic actions in the mouse, localized supraspinally, were antagonized by the selective mu1 antagonist naloxonazine and it had no respiratory depressant actions. Other binding studies suggested the presence of discrete SKF10, 047-selective (KD approximately 5 nM) binding sites in rat brain which differed from both kappa sites and the previously reported PCP-binding sigma sites. Additional binding and autoradiograpical studies have also implied the presence of β-endorphin, or epsilon, sites in the CNS.

UR - http://www.scopus.com/inward/record.url?scp=0021047656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021047656&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(83)90470-8

DO - 10.1016/0024-3205(83)90470-8

M3 - Article

VL - 33

SP - 167

EP - 173

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - SUPPL. 1

ER -